NitroMed, Inc.
NitroMed, Inc. company has developed a technique to enhance nitric oxide and add it to drugs to improve their efficiency. Nitric oxide is formed in the body and plays a role in relaxing blood vessels, making it harder for blood platelets to stick to blood vessel walls, and thereby reducing the obstructions that lead to stroke. Its sole product, BiDil, has FDA approval and is specifically indicated for heart disease in self-identified African-Americans, a group that suffers from the disease at a higher rate than other ethnicities. NitroMed was acquired by health care investment group Deerfield Capital Management in 2009.
Contact Details
Executives
President, CEO, and Director, and Interim CFO
Kenneth M. (Ken) Bate
VP Corporate Affairs
Jane A. Kramer